Cipla

Cipla Liabilities

The The Liabilities of Cipla (CIPLA.NS) as of Nov 16, 2026 is 79.76 B INR. In the previous year, The Liabilities was 60.98 B INR — a change of 30.80% (higher).

Liabilities

79.76 BINR

YoY

30.80%

Last updated:

In 2026, Cipla's total liabilities amounted to 79.76 B INR, a 30.80% difference from the 60.98 B INR total liabilities in the previous year.

The Cipla Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2019
86.19 B INR
Jan 1, 2020
76.05 B INR
Jan 1, 2021
65.66 B INR
Jan 1, 2022
59.84 B INR
Jan 1, 2023
57.50 B INR
Jan 1, 2024
59.15 B INR
Jan 1, 2025
60.98 B INR
Jan 1, 2026
79.76 B INR
The Cipla Liabilities history
YEARLiabilitiesYoY
79.76 BINR+30.80%
60.98 BINR+3.09%
59.15 BINR+2.88%
57.50 BINR-3.91%
59.84 BINR-8.87%
65.66 BINR-13.66%
76.05 BINR-11.76%
86.19 BINR+4.11%
82.79 BINR+2.78%
80.55 BINR-13.03%
92.62 BINR+95.58%
47.36 BINR0.00%
47.36 BINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cipla Stock analysis

What does Cipla do? Cipla Ltd is an Indian pharmaceutical company based in Mumbai. The company was founded in 1935 and is now one of the largest producers of generics worldwide. The name "Cipla" is an abbreviation for "Chemical, Industrial & Pharmaceutical Laboratories". Business Model: Cipla specializes in the production of high-quality generics. This means that they manufacture medication that has the same active ingredients as the original drugs. This allows them to offer medication at a significantly lower price. However, Cipla not only offers generics but also develops its own innovative medication. The focus is on therapy areas such as oncology, respiratory diseases, HIV/AIDS, diabetes, and cardiovascular diseases. Divisions: Cipla is divided into several divisions, including generics, specialty drugs, and biologics. The generics division is the company's core competence. Here, Cipla produces a variety of medications in different forms, such as tablets, capsules, suspensions, etc. The specialty drugs division focuses on innovative medications that are usually more expensive than generics. This includes medications for the treatment of cancer or autoimmune diseases. In the biologics division, Cipla produces biotechnology products based on the use of living cells. Products: Cipla offers a wide range of products, including medications for asthma, diabetes, hypertension, and infectious diseases. Some of the most well-known medications are Escitalopram (an antidepressant), Seroflo (an asthma medication), Tenofovir (an HIV medication), and Sorafenib (a cancer medication). The company continuously works on new products and invests heavily in research and development. Cipla also has a social responsibility. The company is involved in the fight against HIV/AIDS and produces life-saving medication for this disease at an affordable price. Furthermore, Cipla has launched a program called "Cipla Foundation" which works towards improving healthcare in developing countries. Overall, Cipla has achieved impressive growth and is now one of the most significant pharmaceutical companies worldwide. The company has proven that it is possible to offer high-quality medication at an affordable price and still be successful. Cipla is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Cipla's Liabilities

Cipla's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Cipla's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Cipla's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Cipla's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Cipla’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Cipla stock

The Liabilities of Cipla is 79.76 B INR in 2026.

The Liabilities of Cipla changed from 60.98 B INR to 79.76 B INR, representing a 30.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Cipla since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Cipla historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Cipla

All Key Metrics — Cipla